Admedus Ltd

Receive alerts
Market Cap:
$35.4 m
52 weeks high
52 weeks low

Filter by article type

Viewing results 1-25 of 225


Admedus' CardioCell biomaterial scaffold technology validated by independent peer-reviewed study

The study had positive outcomes, showing that the valve replacement devices had good durability....

on 24/6/19

Admedus divests Infusion business for $6.3 million in restructure based on ADAPT portfolio growth strategy

The sale enables Admedus to focus its growth and development strategy around its key ADAPT® product portfolio of biomaterial scaffolds used in heart valve repairs. ...

on 31/5/19

Admedus divesting non-core business; to focus on ADAPT product portfolio

The restructure will enable the company to improve working capital management and reduce cash burn through reduction in headcount....

on 13/5/19

Admedus enters into agreement with SIO Partners for $1 million debt facility

The company remains in voluntary suspension to facilitate completion of its recapitalisation plan. ...

on 8/5/19

Admedus in trading halt pending update on Admedus Immunotherapies transaction

Hong Kong investor Sun Bright Holdings is contributing up to $18 million for cancer vaccine and immunotherapies development...

on 15/4/19

Admedus to spin-off immunotherapies business; shares surge

Hong Kong investor Sun Bright Holdings will contribute up to $18 million for cancer vaccine and immunotherapies development. ...

on 10/4/19

Admedus in trading halt with sale transaction news pending

The trading halt will remain in place until an announcement is made or until the beginning of trade on April 12, 2019. ...

on 10/4/19

Admedus delivers results with heart-driven corporate strategy

The company hopes to improve its share price with ADAPT technology successes....

on 29/3/19

Admedus receives European CE Mark for CardioCel 3D® and VascuCel®

CE marking is a certification mark that indicates conformity with European health, safety, and environmental protection standards....

on 11/3/19

Admedus delivers $25.6 million in total group revenue for the 2018 financial year

New sales teams and product expansion led the continued growth in ADAPT sales in all regions for the period ending December 31, 2018. ...

on 1/3/19

Admedus receives first data from animal study on heart valve device

The TAVR heart valve device utilises the company’s ADAPT® technology....

on 19/2/19

Admedus secures $8.6 million as Sio Partners becomes substantial holder

Funds will support the company’s plans to develop its ADAPT portfolio and position itself to develop new products in 2019....

on 21/1/19

Admedus directors show faith in company by participating in rights issue

The partially underwritten issue closed earlier this month and raised $18.96 million....

on 24/12/18

Admedus closes rights issue, secures $18.9 million

The company can raise an additional $1.2 million by placing the shortfall within three months....

on 17/12/18

Admedus appoints Star Bright nominees as non-executive directors

Both Ms Zhang and Dr Wu bring commercial and scientific experience and networks in China....

on 12/12/18

Admedus appoints new chief medical officer to focus on growth opportunities

Dr Kiran Bhirangi has a deep knowledge of international regulatory and reimbursement environments, having worked across device development, launch and evaluation. ...

on 4/12/18

Admedus returns to exchange and launches a $20.2 million capital raising

Shareholders can subscribe for new shares or transfer their entitlements....

on 28/11/18

Admedus appoints experienced finance executive as interim CFO

Matthew McDonnell served more than 24 years at KPMG, including 10 years as a partner. ...

on 26/11/18

Admedus reports $6.3 million revenues amid $12.7 million Star Bright backing

The voluntarily-suspended company is progressing an ongoing recapitalisation plan....

on 13/11/18

Admedus appoints Steve Denaro to the board

The company has developed heart valve technology and has an immunotherapy business....

on 1/11/18

Admedus completes placement to strategic cornerstone investor Star Bright Group

The latest investment takes Star Bright’s total interest in the company to 19.99% of issued shares....

on 18/9/18

Admedus receives $3.425 million in funds from further Star Bright placement

The Hong Kong-based investment company now holds a significant interest of 19.99%....

on 5/9/18

Admedus secures strategic cornerstone investor from Hong Kong

The deal secures equity funding, a new loan facility and a gateway to the China market....

on 3/9/18

Admedus extends successful distribution deal for medication delivery pumps

The company’s shares are in trading halt since August 2, 2018, pending news of a capital raising....

on 9/8/18